Blocking Piezo2, a protein receptor that senses mechanical forces in tissues — ones such as stress, strain, and stiffness —…
Articles by Steve Bryson, PhD
An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but…
Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced…
The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming…
Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent…
Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy…
Pliant Therapeutics’ bexotegrast reversed the signs of lung scarring, while improving lung function and easing cough severity in people…
Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary…
Pliant Therapeutics’ Phase 2b BEACON-IPF trial testing bexotegrast, an investigational oral treatment, in people with idiopathic pulmonary fibrosis…
GRI Bio has been given the green light to begin a Phase 2a clinical trial testing its lead program candidate…